Dallas, TX (February 7, 2024) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that Dr. Victor Gonzalez will present at the 47th Annual Macula Society Meeting, taking place from Feb 7-10 at the La Quinta Resort & Club in Palm Springs, California. Presentation details are as follows:

Title: MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy Through Week 48 in the Phase 2a STARLIGHT Clinical Trial
Session Title: Inherited Retinal Dystrophy I (Treatment Trials)
Date: February 7, 2024
Time: 6:18 PM-6:25 PM PT
Location: Main Hall
Presenter: Dr. Victor Gonzalez, Valley Retina Institute, McAllen, TX

During his presentation, Dr. Gonzalez will outline the trial design and 48-week data from STARLIGHT (NCT05417126), the first clinical study of optogenetic therapy for severe vision loss from Stargardt disease.  Dr. Gonzalez will cover best-corrected visual acuity (BCVA) improvements of STARLIGHT patients, as measured by ETDRS chart, after a single intravitreal MCO-010 injection. Dr. Gonzalez will also share his thoughts on how the STARLIGHT results can inform the future clinical development of Nanoscope’s Stargardt program as it progresses to Phase 3.

Key results from the STARLIGHT clinical trial

• MCO-010 was well tolerated with no serious adverse events (SAEs) maintained through 48 weeks
• Patients with predominantly macular disease experienced clinically meaningful improvements in BCVA
• Improvements were shown in Visual Field and in patient-reported outcomes (reading and color & contrast)

About Stargardt Disease
Stargardt disease is a rare inherited eye disorder caused by fatty deposits in the macula, leading to center-field loss of vision. It affects approximately 8,000-10,000 patients in the US, often with symptoms beginning in childhood or adolescence. Currently, there are no FDA-approved treatments.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

DALLAS, February 1, 2024 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced a presentation at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2024 Event taking place virtually on Saturday, February 3^rd, Details for the presentation are as follows:

Session Title: Emerging Therapies for Non-Exudative AMD
Title: Optogenetics for Restoring Vision in Geographic Atrophy Secondary to Advanced AMD
Session Date: February 3, 2024
Session Time: 11:30 AM, EST
Location: Virtual
Presenter: Allen C. Ho, MD

During his presentation, Dr. Ho will showcase preclinical results suggesting geographic atrophy from advanced AMD may be amenable to treatment with non-viral, laser-targeted multi-characteristic opsin (MCO) optogenetic therapy, and the potential for clinical translation of Nanoscope’s MCO-020.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

Website: www.nanostherapeutics.com

• FDA and EU Regulators provide consistent advice that visual acuity may serve as primary endpoint to evaluate the effectiveness of MCO-010 in the treatment of low-vision retinitis pigmentosa (RP) patients
• Regulatory feedback provides clarity for potential path to approval in the US and in Europe for MCO-010 in RP; Nanoscope preparing for immediate execution

DALLAS, Jan. 18, 2024 — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (“FDA”) and from the Scientific Advice meeting with the Icelandic Medicines Agency (“IMA”), regarding the regulatory path of MCO-010 for the treatment of RP.

In connection with the productive Type B End-of-Phase 2 discussion with the FDA, Nanoscope received feedback on its MCO-010 optogenetic gene therapy program in patients with severe vision loss from advanced RP. The FDA stated that change from baseline in a measure of visual acuity in low vision patients could be an appropriate primary efficacy assessment in an adequate and well-controlled study to provide substantial evidence of benefit to support BLA approval. MCO-010 has received both orphan drug and fast track designations from the FDA.

Nanoscope also received positive feedback from a Scientific Advice meeting with the IMA as part of the approval path for MCO-010 in Europe.

The IMA endorsed visual acuity as the appropriate primary endpoint to evaluate low-vision RP patients after MCO-010 treatment.

The IMA also endorsed 0.3 logMAR change as being clinically meaningful for the severe vision loss RP patients.

The IMA suggested Nanoscope explore conditional approval for MCO-010 in Europe based on the existing data.

Based on regulatory discussions, Nanoscope has reverted to visual acuity as the primary endpoint in the ongoing randomized, double-masked, multicenter Phase 2b study (RESTORE). The end-of-study, 100-week data are expected to be reported in H1 2024.

“Consistent input from both the FDA and IMA on the potential for visual acuity to serve as the primary endpoint for the clinical program is a major milestone for Nanoscope and provides MCO-010 with a clear regulatory path in the US and in Europe,” said Sulagna Bhattacharya, Co-founder, and CEO of Nanoscope.

About Retinitis Pigmentosa
Retinitis Pigmentosa (RP) encompasses a group of rare genetic disorders in which the retina’s photoreceptor cells degrade over time, leading to impaired vision and eventual blindness. These disorders are believed to be linked to over 100 different gene mutations. Approximately 100,000 people in the U.S. and an estimated 2 million people worldwide suffer from RP, making it the leading cause of inheritable blindness.

About MCO-010
Current gene therapies aim to treat patients with specific gene mutations, and are further limited in advanced disease with degenerated outer retina cells. Ambient-light activatable MCO optogenetic monotherapy targets abundant inner retinal neurons and has the potential to restore vision permanently lost due to advanced RP. MCO-010 (sonpiretigene isteparvovec, suspension for intravitreal injection) is the only broadband, fast, and most-light sensitive opsin currently in clinical trials. With bipolar cell targeting via mGluR6 promoter-enhancer, the MCO-010 expression cassette is designed for restoring high quality vision in real-world environments. The proprietary AAV2 vector allows robust transduction of MCO-010 in bipolar cells upon intravitreal injection. The Phase 1/2 study of MCO-010 in advanced RP patients demonstrated favorable safety and dose-dependent improvement in visual acuity. Nominally significant visual acuity improvements in MCO-010 treated patients were observed in comparison to control in Phase 2b RESTORE trial. There were also nominally significant functional vision improvements as assessed by multi-luminance vision-guided mobility and shape discrimination, along with a favorable safety profile.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, TX — Jan. 12, 2024  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that Dr. Samarendra Mohanty, President & Chief Scientific Officer, and Dr. Jared Stephens, Vice President of Strategy & Business Development will be presenting at the 20th Annual Advanced Therapies Week Conference taking place from January 16-19 at the Miami Convention Center in Miami, Florida. Details for the presentation are as follows:

Title: Navigating the manufacturing and associated regulatory challenges for advancing gene therapies
Session Title: Regulatory and CMC Alignment for Gene Therapy Manufacturing
Session Date: January 17, 2024
Session Time: 4:00 p.m. E.T.
Location: Theatre 2
Presenter: Samarendra Mohanty, PhD, President & Chief Scientific Officer

During his presentation, Dr. Mohanty will:

• Introduce the need for forward-thinking strategies in transitioning from experimental processes to commercially viable ones
• Cover the regulatory landscape, challenges of limited historical data, and comparability of manufacturing batches
• Highlight the importance of risk assessment in justifying the analytical approach and how this can influence decision-making

Title: Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration 

Session Title:  Gene Therapy Highlight Session
Session Date: January 19, 2024
Session Time: 10:00 a.m. E.T.
Location: Innovation Stage
Presenter: Jared Stephens, PhD, Vice President of Strategy and Business Development

During his presentation, Dr. Stephens will highlight the recent clinical progress of Nanoscope’s Multi-Characteristic Opsin pipeline programs for Retinitis Pigmentosa and Stargardt Macular Degeneration.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

Dallas, TX – December 4, 2023 – Nanoscope Therapeutics (Nanoscope), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. With more than 30 years of exemplary experience marked by extensive executive leadership in the ophthalmic industry, Mr. Sblendorio will support Nanoscope in reaching its strategic vision.

In his new role as Chairman of the Board, Mr. Sblendorio will play a pivotal role in ensuring the effectiveness of the board of directors in implementing Nanoscope’s organizational strategy and direction. His comprehensive understanding of finance and business development will assist in guiding Nanoscope through its mission to bring hope for renewed sight to millions of people affected by retinal degenerative diseases for which no cures currently exist.

Mr. Sblendorio remarked on his appointment, “I am honored to join Nanoscope as Chairman of the Board. The company’s commitment to advancing novel treatments for retinal degenerative diseases aligns with my passion for making a meaningful impact in the retina space. I look forward to working collaboratively with the board and leadership team to drive innovation and contribute to the realization of our shared mission.”

Most recently, Mr. Sblendorio held various key leadership roles at IVERIC bio, Inc., an Astellas Company (formerly Ophthotech Corporation), including CEO, President, and Director. He also served as EVP, COO, CFO and Treasurer. Additionally, he served as President, CFO and Director at The Medicines Company and as EVP and CFO at Eyetech Pharmaceuticals. Earlier in his career, Mr. Sblendorio was a Managing Director at MPM Capital Advisors, LLC, and held various senior financial positions at Hoffman-La Roche.

Nanoscope CEO and Co-Founder Sulagna Bhattacharya expressed enthusiasm about the appointment, stating, “We are elated to welcome Glenn Sblendorio as our Chairman of the Board. His wealth of experience in building and scaling progressive companies, coupled with his thorough knowledge of successfully bringing retinal treatments to market, will undoubtedly strengthen Nanoscope’s position as a leader in the ophthalmic industry. We look forward to leveraging his expertise as we navigate the next phases of our development.”

Mr. Sblendorio joins the company at a crucial time, and his appointment reflects Nanoscope’s commitment to optimizing the impact of the board of directors by assembling a group of diverse and accomplished advisors to drive the organization’s innovation and success. Nanoscope is dedicated to pioneering novel retinal solutions that make a lasting impact for patients and physicians.

About Nanoscope
www.nanostherapeutics.com
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

For media inquiries, please contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

DALLAS, Dec. 1, 2023 — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Francesco Bandello, MD, FEBO, will present at the 11^th Annual FLORetina Congress taking place from November 30 – December 3, 2023 in Rome, Italy. Details for the presentation are as follows:

Title: Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss due to Retinitis Pigmentosa

Session: Highlighted Free Papers Innovative Therapies
Session Date: December 2, 2023
Session Time: 10:54 a.m. C.E.T.
Location: Cavalieri Waldorf Astoria Hotel & Congress Center
Presenter: Francesco Bandello, MD, FEBO, Professor and Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele, Milan

In his presentation, Professor Bandello will discuss the 12-month data from Nanoscope’s RESTORE Phase 2b randomized, controlled trial in patients with advanced retinitis pigmentosa.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126 ). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Nov. 30, 2023 — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Jared Stephens, PhD, Vice President of Strategy and Business Development, will present at the 13^th Annual Ophthalmology Innovation Summit (OIS) taking place from December 1-2 in San Diego, California. Details for the presentation are as follows:

Title: Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration

Session Title: Retina Innovation Showcase
Session Date: December 2, 2023
Session Time: 11:05 a.m. E.T.
Location: Omni Hotel San Diego
Presenter: Jared Stephens, PhD, Vice President of Strategy and Business Development

During his presentation, Dr. Stephens will provide a corporate update on Nanoscope’s recent and upcoming activities.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Nov. 9, 2023  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Dr. Samarendra Mohanty, President and Chief Scientific Officer will participate in a panel and present at the 4^th Annual Dry AMD Therapeutic Development Summit taking place from November 14-16, 2023 in Boston, Massachusetts. Details for the panel and presentation are as follows:

Title: Overcoming the Limitations of Dry AMD not having a Recognised Disease Model
Session: Navigating how to Optimize Current Dry AMD In Vivo & In Vitro Models to Improve Efficacy
Session Date: November 15, 2023
Session Time: 11:00 a.m. E.T.
Location: Hilton Boston Logan Airport

During the panel discussion, Dr. Mohanty will highlight the reasons why developing a relevant animal model for dry AMD remains a pertinent challenge. He will also explore ways to incorporate more NHPs in preclinical testing to better inform the safety profile of dry AMD therapeutics.

Title: Expanding Optogenetics Vision Restoration to GA via Laser Delivery of Multi-Characteristic Opsin
Session: Investigating the Latest Advancements for Improving the Delivery of Dry AMD Therapeutics
Session Date: November 16, 2023
Session time: 4:00 p.m. E.T.
Location: Hilton Boston Logan Airport

In his presentation, Dr. Mohanty will discuss the prospect of optogenetics to improve visual acuity in macular degeneration patients from proof-of-concept data obtained in humans, while assessing the latest preclinical data on the use of the laser delivery of Multi-Characteristic Opsin (MCO). He will also discuss the platform’s potential to treat different retinal degenerative conditions.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy, secondary to AMD.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, TX (November 3, 2020) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), has been awarded “Best of Show for Retina” at Eyecelerator@AAO2023. The award was presented to Nanoscope’s Chief Medical Officer, Samuel Barone, MD, for his presentation during the event’s Retina Showcase.  In his presentation Dr. Barone showcased the company’s Multi-Characteristic Opsin platform and its potential to restore vision based on recent clinical data in patients with advanced retinal degenerative diseases.

Sam Barone, MD, Chief Medical Officer of Nanoscope Therapeutics accepts the “Best of Show – Retina” award during Eyecelerator@AAO2023 in San Francisco, November 2, 2023

Recipient of the Best of Show Award is chosen by a vote of conference attendees. “We are thrilled and honored for this recognition,” said Sulagna Bhattacharya, CEO, “It is very special because it comes from our own retina community. We thank you all for the encouragement. It means a great deal to our entire team.”

“The patient experience was front and center in my presentation, and I appreciate the acknowledgment of our work to make a difference in their lives,” said Samuel Barone, CMO.

Nanoscope Therapeutics leadership celebrates “Best of Show” award at Eyecelerator. From left, Jared Stephens, VP Strategy & Business; Samarendra Mohanty, Co-Founder & President; Sam Barone, Chief Medical Officer; Sulagna Bhattacharya, CEO; Michael Marquez, CFO.

Eyecelerator@AAO2023 took place on November 2, 2023 in advance of the American Academy of Ophthalmology Annual Meeting in San Francisco.  Eyecelerator focuses on emerging trends, advancements and innovations in eyecare.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Oct. 30, 2023 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and Eyecelerator @ AAO 2023 taking place in San Francisco, California. Details for the presentations are as follows:

Eyecelerator @ AAO 2023
Session Title: Retina Showcase
Session Date: November 2, 2023
Session Time: 12:40 p.m. P.T.
Location: San Francisco Marriott Marquis, Nob Hill Room
Presenter: Samuel Barone, M.D., Chief Medical Officer

During his presentation, Dr. Barone will showcase our Multi-Characteristic Opsin platform and its potential to restore vision based on recent clinical data in patients with advanced retinal degenerative diseases.

American Academy of Ophthalmology (AAO) 2023 Annual Meeting
Title: MCO-010 optogenetic therapy for vision loss in Stargardt disease: Topline data from the Phase 2 STARLIGHT trial
Session Title: RET14 (Section XI: Late Breaking Developments, Part II)
Session Date: November 4, 2023
Session Time: 9:10 a.m. P.T. (In Person, Live Broadcast, On Demand)
Location:  Moscone Center, West Building – Rm. 3004
Presenter: Stephen H. Tsang, M.D., Ph.D.

During his presentation, Dr. Tsang will discuss end-of-study data from our Phase 2 STARLIGHT trial of MCO-010 therapy in patients with severe vision loss due to Stargardt disease.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Oct. 26, 2023 / — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Najam Sharif, PhD, DSc, a veteran in drug/device discovery and development, as Vice President of Global Research and Development.

“We are delighted to welcome Naj to the Nanoscope team,” said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope. “His extensive experience in ophthalmology and pharmaceutical drug discovery and development is a natural fit for our organization, and we look forward to drawing on his clinical and regulatory expertise in particular at this pivotal time for MCO-010.”

“I am honored to join Nanoscope, a company that I see as transformative in the field of ophthalmology. As their lead asset, MCO-010, advances toward FDA approval, I look forward to the opportunity to positively impact the lives of people living with inherited retinal diseases, and to bring treatment options to a population for which there are no established cures,” said Dr. Sharif.

Dr. Naj Sharif brings over three decades of experience in pharmaceutical drug/device discovery and development to Nanoscope, including specialized expertise in ophthalmology and neuroscience. Throughout his career, he contributed to the discovery and development of several FDA-approved commercial drugs, including anti-glaucoma agent Travatan® and anti-allergic/inflammatory drugs such as Patanol® /Pataday® and Emedine®. In addition, Dr. Sharif was instrumental in guiding three drugs through to FDA approvals: Simbrinza® for glaucoma, IZBA® for the treatment of ocular hypertension and glaucoma, and PAZEO™ for the treatment ocular allergies. Most recently, Dr. Sharif served as Vice President, Global Biomedical Sciences & Head of Glaucoma and Neuroprotection at Santen, where he managed the company’s Clinical Sciences, Data Sciences, and Biometrics departments, and where he also established and directed Global Alliances & External Research activities. Prior to this, he held positions related to R&D and regulatory affairs at Alcon Research-Novartis, Synaptic Pharmaceutical Corp, and Syntex Pharma / Roche Pharmaceutical Corp. He is widely published with an extensive number of peer-reviewed publications, edited books and holds multiple patents for mitigation of neurological and ophthalmic diseases.  He has been an invited organizer, chairman and speaker at multiple national and international conferences.

In addition to his professional experience, Dr. Sharif has served on numerous boards and committees. Dr. Sharif is an elected Fellow of multiple learned societies such as Association for Research in Vision and Ophthalmology, Association for Ocular Pharmacology and Therapeutics and British Pharmacological Society. Currently he serves on the Scientific Advisory Board of the Glaucoma Foundation and as an adjunct professor for the Duke-NUS Medical School in Singapore, and Institute of Ophthalmology at University College London. He is the recipient of several honors, including the Ernst H. Barany prize for “Outstanding Contributions to Ocular Pharmacology”, the first and inaugural “Dr. Roger Vogel Award” for Pharmaceutical Research, and the Sir James Black Award for “Contributions to Drug Discovery”.

Dr. Sharif received a PhD in neuroscience, DSc (by thesis) in ophthalmology, and dual bachelor’s degree in physiology and biochemistry from the University of Southampton (UK).

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, TX (October 9, 2023) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Dr. Arup Roy, and Michael Carlson will present at the 13^th The Eye and The Chip World Research Congress taking place from October 8-10 in Southfield, Michigan. Details for the presentations are as follows:

Title: Development and Validation of the Multi-Luminance Y-Mobility Test (MLYMT)) for Assessment of Vision-Guided Mobility in Patients with Profound Vision Loss

Session Title: Session Ten: Psychophysics continued
Session Date: October 10
Session Time: 10:00-10:30 a.m. E.T.
Location: The Westin Southfield Hotel
Presenter: Arup Roy, Ph.D.

During his talk, Dr. Roy will discuss development and validation of novel mobility based functional vision assessment by MLYMT using longitudinal data from subjects with different levels of vision, evaluated by masked graders.

Title: Development and Validation of the Multi-Luminance Shape Discrimination Test (MLSDT) for Assessment of Near Object Recognition in Profoundly Vision Impaired Patients

Session Title: Group “A” Poster Presenters
Session Date: October 9
Session Time: 6:00-7:00 p.m. E.T.
Location: The Westin Southfield Hotel
Presenter: Michael Carlson
During his poster presentation, Mr. Carlson will discuss development and validation of novel near-object functional vision assessment by MLSDT using data from subjects with different levels of vision collected at multiple time points. 

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

DALLAS, Oct. 9, 2023 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and macular degenerations, today announced presentations at The Retina Society 56^th Annual Scientific Meeting taking place in New York, New York from October 11-14, 2023.

Details for the presentations are as follows:

Title: MCO-010 Optogenetic Vision Restoration in Retinitis Pigmentosa Patients with Profound Vision Loss: A Randomized, Sham-Controlled, Multi-center, Double-Masked Clinical Trial (RESTORE)

Session Title: Genetic Diseases, Dystrophies & Degenerations
Session Date: October 11, 2023
Session Time: 4:56 p.m. E.T.
Location: Intercontinental Barclay Hotel
Presenter: Christine Kay, M.D., Director of Electrophysiology, Retinal Genetics, and Clinical Trials at Vitreoretinal Associates in Gainesville, Florida, and Affiliate Assistant Professor at the University of South Florida.

In her presentation, Dr. Kay will discuss clinical data and analysis from Nanoscope’s Phase 2b RESTORE trial in patients with advanced retinitis pigmentosa.

Title: MCO-010 Optogenetic Therapy for Profound Vision Loss in Stargardt Disease: 12-Month Outcomes from the Phase 2 STARLIGHT Trial

Session Title: Imaging
Session Date: October 12, 2023
Session Time: 5:02 p.m. E.T.
Location: Intercontinental Barclay Hotel
Presenter: Allen Ho, M.D., Professor of Ophthalmology at Thomas Jefferson University and Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital.

In this late-breaking presentation, Dr. Ho will discuss recent 1 year data from Nanoscope’s Phase 2 STARLIGHT trial of MCO-010 therapy in patients with advanced Stargardt macular degeneration.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Oct. 2, 2023  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place in Amsterdam, The Netherlands. Details for the presentations are below:

Ophthalmology Futures Retina Forum

Panel Discussion: Visual Preservation in Retinal Diseases: Will Gene Therapy Make a Dent?
Session Date: October 4, 2023
Session Time: 12:30-1:00 p.m. CEST
Location: Hyatt Regency Hotel
Presenter: Dr. Samarendra Mohanty, President and Chief Scientific Officer

On the panel, Dr. Mohanty will highlight gene-agnostic approaches that have the potential to affect large patient populations with retinal degeneration diseases.

Title: Pioneering a New Wave of Optogenetic Therapies for Vision Restoration
Session Date: October 4, 2023
Session Time: 2:38-2:45 p.m. CEST
Location: Hyatt Regency Hotel
Presenter: Dr. Samarendra Mohanty, President and Chief Scientific Officer

In this session, Dr. Mohanty will highlight Nanoscope’s Multi-Characteristic Opsin platform and recent clinical data from the clinical trials for patients with advanced retinitis pigmentosa and Stargardt disease.

Euretina Innovation Spotlight (EIS)
Title: Pioneering a New Wave of Optogenetic Therapies for Vision Restoration
Session Date: October 4, 2023
Session Time: 1:00 – 7:40 p.m. CEST
Location: Euretina Congress Centre (RAI) Amsterdam
Presenter: Sulagna Bhattacharya, Chief Executive Officer

In this poster session, Ms. Bhattacharya will highlight Nanoscope’s Multi-Characteristic Opsin and Non-viral Laser delivery platform technologies for advancing Nanoscope’s pipeline of inherited retinal disorders and advanced age-related macular degeneration.

23^rd Euretina Congress
Abstract Title: MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial
Session Title: Euretina Session 6 – Landmarks & Late Breakings
Session Date: October 6, 2023
Session Time: 12:15-1:15 p.m. CEST
Location:  RAI Amsterdam
Presenter: Michael Singer, M.D., Clinical Professor of Ophthalmology at the University of Texas Health Science Center

In his session, Dr. Singer will discuss recent data from Nanoscope’s Phase 2 STARLIGHT trial of MCO-010 therapy in patients with advanced Stargardt macular degeneration.

Abstract Title: Optogenetic therapy with MCO-010 in severe sight loss due to retinitis pigmentosa: 12-month results from the RESTORE randomized, placebo-controlled double-masked clinical trial
Session Details: Available as an audio-narrated free paper viewable at the event or on the virtual congress platform at 4:00 p.m. CEST on October 5, 2023.
Location:  RAI Amsterdam
Presenter: SriniVas R. Sadda, M.D., President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan – Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA), David Geffen School of Medicine

Dr. Sadda will discuss clinical data and analysis from Nanoscope’s Phase 2b RESTORE trial in patients with advanced retinitis pigmentosa.

Abstract Title: Design and Development of Two Novel Assessments of Vision Dependent Function in Patients with Severe Vision Impairment due to Retinitis Pigmentosa Receiving MCO-010
Session Details: Available as an audio-narrated free paper viewable at the event or on the virtual congress platform at 4:00 p.m. CEST on October 5, 2023.
Location: RAI Amsterdam
Presenter: Victor Gonzalez, M.D., Valley Retina Institute, McAllen, TX

Dr. Gonzales will discuss the validation of two novel functional vision endpoints, mobility and object recognition, suitable to assess low-vision patients such as those with advanced retinitis pigmentosa.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, TX (September 28, 2023) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that Dr. Sam Barone, Chief Medical Officer, will give a presentation on the clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform at the 4^th Annual Gene Therapy for Ophthalmic Disorders Summit taking place from October 3-5 in Boston, Massachusetts. Details for the presentation are as follows:

Title: Progressing Optogenetic Gene Therapies Through the Clinic

Session Title: Optogenetics & Mutation-Independent Vision Restoration in the Clinical Setting
Session Date: October 4, 2023
Session Time: 12:20 p.m. E.T.
Location: Hilton Boston Back Bay
Presenter: Sam Barone, M.D., Chief Medical Officer

During his presentation, Dr. Barone will introduce and highlight the benefits of Nanoscope’s proprietary MCO gene therapies for patients with inherited retinal dystrophies (IRDs).  Additionally, Dr. Barone will discuss clinical data from RESTORE, a Ph2b multi-center, randomized controlled trial of lead asset MCO-010 in patients with advanced Retinitis. Pigmentosa.  Recent clinical progress from STARLIGHT, a Ph2 multi-center open-label trial of MCO-010 in patients with advanced Stargardt Macular Degeneration will also be presented. 

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

DALLAS, Sept. 21, 2023  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, announced today the appointment of Samuel Barone, M.D., an accomplished leader in the pharmaceutical space and former FDA official, as Chief Medical Officer.

“We are thrilled to welcome Dr. Barone to the Nanoscope team. The regulatory expertise garnered during his tenure at the FDA will be instrumental as we continue to advance our pipeline through late-stage clinical development and navigate the regulatory process,” said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope. “Dr. Barone will support our mission to bring sight-restoring therapies to patients with inherited retinal diseases in an expeditious manner.”

“Nanoscope has the potential to impact the treatment landscape with its gene-agnostic, sight-restoring optogenetic therapies and bring these transformative therapeutic options to patients with severe vision loss due to inherited retinal diseases, for which there are no restorative therapies available,” said Dr. Barone. “I look forward to taking MCO-010 through approval and advancing Nanoscope’s follow-on assets to the clinic.”

Dr. Samuel Barone is a board-certified ophthalmologist and vitreoretinal surgeon with clinical development and regulatory experience across a range of indications in ophthalmology, dermatology, rare diseases, and cell and gene therapy. He was most recently Chief Medical Officer at Gemini Therapeutics prior to its merger with Disc Medicine, where he oversaw the development of novel therapeutics targeting the complement system to treat genetically defined age-related macular degeneration and systemic renal disease. Prior to that he was Chief Medical Officer for Veloce BioPharma, a topical therapeutics company focusing on unmet clinical needs in dermatology, ophthalmology and supportive oncology. He was also Chief Medical Officer for Avalanche Biotechnologies and then Senior Vice President, Clinical Development, for Adverum Biotechnologies. Both roles included supervision and implementation of the clinical development of AAV-based gene therapy products targeting unmet medical needs in ophthalmology and rare diseases. Early in his career, he served on active duty as a flight surgeon for the United States Air Force.

As a Senior Medical Officer at the FDA in the Office of Cellular, Tissue and Gene Therapies (now the Office of Therapeutic Products), he served as a subject matter expert and developed FDA Guidance Documents. He has global experience in overseeing clinical trials in the U.S. as well as in Australia and India. He was involved with Nanoscope for the Phase 1/2a clinical trial design for MCO-010.

Dr. Barone received an M.D. from The Pennsylvania State University College of Medicine. He completed a residency in ophthalmology at The New York Eye and Ear Infirmary and a medical and surgical retina fellowship at the University of California, San Diego.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed their end-of-study visit for the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Aug. 9, 2023  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company focused on gene therapies for retinal degenerative diseases, presented key results from its Phase 2 clinical trial, STARLIGHT, at the American Society of Retina Specialists (ASRS) annual meeting in Seattle last week. The trial evaluated the effects of their novel therapeutic, MCO-010, for patients with Stargardt disease, a condition currently lacking available treatments.

Key results from the STARLIGHT clinical trial:

• Patients treated with MCO-010 demonstrated clinically meaningful improvements in best-corrected visual acuity (BCVA)
• An approximate 3 dB gain in mean sensitivity, as measured by Octopus visual field perimetry
• No serious adverse events (SAEs) were observed in patients treated with MCO-010 in this study

“I appreciated the opportunity to present on the promising results of Nanoscope’s Phase 2 STARLIGHT clinical trial. With no current treatment options, MCO-010 may bring hope to those patients with severe vision loss due to Stargardt disease by restoring broadband light sensitivity,” said Dr. Allen Ho, Professor of Ophthalmology at Thomas Jefferson University and Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital.

“We are thrilled to have had Dr. Allen Ho present the Phase 2 STARLIGHT clinical trial data at this year’s ASRS. MCO-010 is advancing our proprietary AAV gene therapy platform with the potential to improve vision for patients with Stargardt disease and other inherited retinal diseases (IRDs). These results offer promising prospects for addressing this challenging disease,” said Sulagna Bhattacharya, Chief Executive Officer & Co-Founder of Nanoscope.

About Stargardt Disease
Stargardt disease is a rare inherited eye disorder caused by fatty deposits in the macula, leading to center field loss of vision. It affects approximately 8,000-10,000 patients in the U.S., often with symptoms beginning in childhood or adolescence. Currently, there are no FDA-approved treatments.

About Nanoscope Therapeutics, Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also fully enrolled a Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
pr@nanostherapeutics.com

REFERENCE: Ho, et al. MCO-010 optogenetic therapy for severe vision loss in Stargardt disease: 6-month outcomes from the Phase 2 STARLIGHT trial. ASRS 2023.

SOURCE Nanoscope Therapeutics

DALLAS, TX (July 21, 2023) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation at the 2023 ASRS Annual Scientific Meeting taking place from July 28-August 1, 2023 in Seattle, Washington. The management team will be in attendance at the conference and accessible for meetings.

Details for the presentation are as follows:

Abstract Title: MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes from the Phase 2 STARLIGHT Trial

Paper Type: Late Breaking Presentation

Session Title: Hereditary Retinal Disease & Genetics Symposium

Session Date: Monday, July 31, 2023

Session Time: 4:30 PM PT

Presenter: Allen C. Ho, MD, FASRS, Professor of Ophthalmology at Thomas Jefferson University and Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital

Dr. Ho will present the safety and efficacy results obtained from the Phase 2 STARLIGHT trial focusing on Stargardt disease. These outcomes will play a vital role in shaping the future clinical development of MCO-010 optogenetic therapy, aimed at restoring vision in patients with Stargardt macular degeneration and other retinal degenerative diseases.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also fully enrolled a Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

DALLAS, June 12, 2023 /PRNewswire/ — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Sulagna Bhattacharya, Co-Founder and Chief Executive Officer, Dr. Samarendra Mohanty, Co-Founder and President, and Dr. Victor Hugo Gonzalez, Valley Retina Institute, will participate in a fireside chat at Baird’s Biotech Discovery Series. The fireside chat is scheduled to be held on Friday, June 23, 2023, at 10:30 a.m. ET.

To register for the live webcast, please contact your Baird representative. A replay of the webcast will be available through Baird for a limited time following the event.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also fully enrolled a Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com